Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors

被引:0
作者
CordonCardo, C
Zhang, ZF
Dalbagni, G
Drobnjak, M
Charytonowicz, E
Hu, SX
Xu, HJ
Reuter, VE
Benedict, WF
机构
[1] MEM SLOAN KETTERING CANC CTR,DEPT EPIDEMIOL & BIOSTAT,NEW YORK,NY 10021
[2] MEM SLOAN KETTERING CANC CTR,DEPT SURG,SERV UROL,NEW YORK,NY 10021
[3] MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030
[4] MD ANDERSON CANC CTR,DEPT MOL ONCOL,HOUSTON,TX 77030
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Altered patterns of p53 and PRE expression have been reported to be frequent events and to have prognostic significance in bladder cancer, To assess the potential adverse consequences of having altered patterns of both p53 and pRB proteins in patients with bladder neoplasms compared with having one or neither abnormality, we have studied a cohort of superficial transitional cell carcinomas of the urinary bladder by immunohistochemical analysis, The present study included 59 well-characterized superficial transitional cell carcinomas (Ta, n = 28; T1, n = 31) for which clinicopathological variables were available, Nuclear overexpression of p53 was identified in 22 cases (37%), A statistically significant association was observed between the p53-positive phenotype and disease progression (P < 0.001), as well as reduced survival (P < 0.001), Undetectable levels of pRB were observed in 11 cases (19%), Patients with a pRB-negative phenotype had a more frequent disease progression (P = 0.014) and decreased overall survival (P = 0.014), We also observed a significant association between altered p53 and undetectable pRB expression patterns (P = 0.001), Nine tumors showed both a p53-positive and a pRB-negative phenotype, There was an even more marked increase in progression (P = 0.00005) and decreased overall survival (P = 0.0004) in patients whose tumors had both alterations after controlling for tumor stage, tumor grade, and suspicion of vascular invasion, These data suggest that alterations of p53 and pRB have a cooperative negative effect on both progression and survival in primary bladder cancer, It may be postulated that aberrant p53 and pRB expression deregulates cell cycle control at the G(1) checkpoint and engenders tumor cells with reduced response to programmed cell death, The imbalance produced by an enhanced proliferative activity and a decreased apoptotic rate may determine the aggressive clinical course of the bladder tumors harboring both p53 and pRB alterations.
引用
收藏
页码:1217 / 1221
页数:5
相关论文
共 42 条
[1]  
*AM JOINT COMM CAC, 1986, EUR J BIOCHEM, V159, P529
[2]   ISOLATION OF HUMAN-P53-SPECIFIC MONOCLONAL-ANTIBODIES AND THEIR USE IN THE STUDIES OF HUMAN P53 EXPRESSION [J].
BANKS, L ;
MATLASHEWSKI, G ;
CRAWFORD, L .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 159 (03) :529-534
[3]   THE RETINOBLASTOMA PROTEIN IS PHOSPHORYLATED DURING SPECIFIC PHASES OF THE CELL-CYCLE [J].
BUCHKOVICH, K ;
DUFFY, LA ;
HARLOW, E .
CELL, 1989, 58 (06) :1097-1105
[4]   THE E2F TRANSCRIPTION FACTOR IS A CELLULAR TARGET FOR THE RB PROTEIN [J].
CHELLAPPAN, SP ;
HIEBERT, S ;
MUDRYJ, M ;
HOROWITZ, JM ;
NEVINS, JR .
CELL, 1991, 65 (06) :1053-1061
[5]  
CORDONCARDO C, 1994, CANCER RES, V54, P794
[6]   P53 MUTATIONS IN HUMAN BLADDER-CANCER - GENOTYPIC VERSUS PHENOTYPIC PATTERNS [J].
CORDONCARDO, C ;
DALBAGNI, G ;
SAEZ, GT ;
OLIVA, MR ;
ZHANG, ZF ;
ROSAI, J ;
REUTER, VE ;
PELLICER, A .
INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (03) :347-353
[7]   ALTERED EXPRESSION OF THE RETINOBLASTOMA GENE-PRODUCT - PROGNOSTIC INDICATOR IN BLADDER-CANCER [J].
CORDONCARDO, C ;
WARTINGER, D ;
PETRYLAK, D ;
DALBAGNI, G ;
FAIR, WR ;
FUKS, Z ;
REUTER, VE .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (16) :1251-1256
[8]  
COX DR, 1975, BIOMETRIKA, V62, P269, DOI 10.1093/biomet/62.2.269
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]   THE PRODUCT OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE HAS PROPERTIES OF A CELL-CYCLE REGULATORY ELEMENT [J].
DECAPRIO, JA ;
LUDLOW, JW ;
LYNCH, D ;
FURUKAWA, Y ;
GRIFFIN, J ;
PIWNICAWORMS, H ;
HUANG, CM ;
LIVINGSTON, DM .
CELL, 1989, 58 (06) :1085-1095